**Excerpt**

“Although the four agents are not named in the bill, that description applies to Omidria, Amyvid, PuraPly and Lumason, ADVI Director Lindsay Bealor Greenleaf told the Pink Sheet. The bill also directs the General Accountability Office to conduct a study on the impact of “packaging” high cost agents after pass-through status has expired.”

***
[/el-text]

View full article here